1629760-28-6

1629760-28-6 structure

Name: Ladiratuzumab
Chemical Name: Ladiratuzumab
CAS Number: 1629760-28-6
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Cancer
Create Date: 2023-04-27 16:57:11
Modify Date: 2025-11-29 23:25:10
Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer[1][2].

Name	Ladiratuzumab

Description	Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
References	[1]. Trail PA, et al. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. Pharmacol Ther. 2018 Jan;181:126-142. [2]. Li F, et al. Preclinical combinations of the antibody-drug conjugate SGN-LIV1A with chemotherapies show increased activity[J]. Cancer Research, 2016, 76(14_Supplement): 2966-2966.

No Any Chemical & Physical Properties